Dong Hu

168 Taifeng Road
Huainan, 232001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Identification of capsazepine as a novel anti-silicosis agent via TRPV1/PI3K/AKT axis inhibition.

Identification of capsazepine as a novel anti-silicosis agent via TRPV1/PI3K/AKT axis inhibition.

Journal: European journal of pharmacology

Published: April 25, 2026

Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway.

Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway.

Journal: International immunopharmacology

Published: February 15, 2026

Abrogation of PDE7A ameliorates alveolar epithelial EMT-Driven pulmonary fibrosis.

Abrogation of PDE7A ameliorates alveolar epithelial EMT-Driven pulmonary fibrosis.

Journal: Biochemical pharmacology

Published: November 19, 2025

Cortex Mori Radicis Mitigates Inflammation and Fibrosis in Pulmonary Fibrosis Through PI3K/AKT Pathway Suppression.

Cortex Mori Radicis Mitigates Inflammation and Fibrosis in Pulmonary Fibrosis Through PI3K/AKT Pathway Suppression.

Journal: Canadian respiratory journal

Published: August 12, 2025

The research on the mechanism of GBP2 promoting the progression of silicosis by inducing macrophage polarization and epithelial cell transformation

The research on the mechanism of GBP2 promoting the progression of silicosis by inducing macrophage polarization and epithelial cell transformation

Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Published: July 07, 2025

BI-2536 attenuates IPF progression by inhibiting the PLK2/JNK/SP1 Signaling pathway in AT2 cells.

BI-2536 attenuates IPF progression by inhibiting the PLK2/JNK/SP1 Signaling pathway in AT2 cells.

Journal: International immunopharmacology

Published: May 27, 2025

Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression.

Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression.

Journal: European journal of pharmacology

Published: April 15, 2025

Peroxiredoxin 4 as a switch regulating PTEN/AKT axis in alveolar macrophages activation.

Peroxiredoxin 4 as a switch regulating PTEN/AKT axis in alveolar macrophages activation.

Journal: Signal transduction and targeted therapy

Published: April 08, 2025

Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway.

Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway.

Journal: Journal of translational medicine

Published: February 27, 2025

Ingenol ameliorates silicosis via targeting the PTGS2/PI3K/AKT signaling axis: Implications for therapeutic intervention.

Ingenol ameliorates silicosis via targeting the PTGS2/PI3K/AKT signaling axis: Implications for therapeutic intervention.

Journal: Cellular signalling

Published: December 31, 2024

Piperine as a promising therapeutic agent for silicosis: Targeting the JAK2-STAT3 signaling pathway and alleviating inflammation and fibrosis.

Piperine as a promising therapeutic agent for silicosis: Targeting the JAK2-STAT3 signaling pathway and alleviating inflammation and fibrosis.

Journal: International immunopharmacology

Published: December 26, 2024

SSBP1 positively regulates RRM2, affecting epithelial mesenchymal transition and cell cycle arrest in human lung adenocarcinoma cells.

SSBP1 positively regulates RRM2, affecting epithelial mesenchymal transition and cell cycle arrest in human lung adenocarcinoma cells.

Journal: Cellular signalling

Published: October 15, 2024

Showing 1-12 of 75

Last Updated: 09/26/2026